Meto vs. Henry Meds: Which Metabolic Health Platform is Right for You?

Henry Meds is a telehealth service focused almost exclusively on prescribing GLP-1 weight loss medications like semaglutide and tirzepatide. The platform offers a direct-to-consumer experience where users complete a brief intake form, get evaluated by a licensed clinician, and, if eligible, receive compounded medications shipped monthly. The service is subscription-based and doesn’t include comprehensive lab work, coaching, or ongoing clinical supervision beyond prescription renewals. Its appeal lies in convenience and fast access to popular medications, especially for users who want to skip traditional weight loss programs or avoid navigating insurance.

Meto, on the other hand, is a doctor-led metabolic health platform that offers far more than prescription access. It addresses the biological, behavioral, and hormonal drivers of weight and chronic disease, combining medical expertise, personalized care plans, AI-powered monitoring, and insurance-compatible services. Rather than simply prescribing GLP-1s, Meto integrates them into a broader clinical strategy that includes lab testing, long-term behavior change, and deprescription support. It’s ideal for individuals dealing with complex metabolic conditions like PCOS, insulin resistance, or perimenopause — or those who want to work with a care team focused on restoring health, not just losing weight.

Features	Meto	Henry Meds
Approach to Care	Medical-led, personalized metabolic and hormonal health care.	Prescription-first, focused on GLP-1 weight loss medication access.
Use of Technology	AI-powered clinical insights, integrated telehealth, lab and wearable integration.	Online intake, telehealth prescription workflow, and medication fulfillment.
Insurance Coverage	Accepts most major insurance providers.	Does not accept insurance; entirely self-pay.
Pricing Model	Copay + optional membership fees (insurance-eligible); transparent pricing.	Monthly cash subscription ($297–$400/month), includes medication.
Clinical Team Availability	Board-certified doctors, metabolic experts, dietitians, coaches.	Prescribing clinicians only; limited ongoing supervision.
Availability	U.S.-based, expanding coverage.	Available in most U.S. states for eligible users.
Program Flexibility	Plans adapted to metabolic profile, labs, hormone levels, and patient goals.	One-size-fits-most prescription protocol.
Patient Support	Dedicated care team with ongoing guidance and 1:1 communication.	Customer support via chat; limited medical interaction.
Mobile & Web Experience	Mobile/web app with analytics, clinical dashboards, remote monitoring.	Website-based onboarding and account access.
Community and Peer Support	Clinically moderated groups and educational content.	No structured community or peer support.

Henry Meds approaches weight loss through the lens of medication access. Their core philosophy is simple: GLP-1 medications like semaglutide work — so make them easier to get. The platform minimizes friction by offering an online intake and a predictable, self-pay monthly fee that covers prescriptions and shipping. There’s little focus on lifestyle change, behavioral coaching, or the root causes of weight gain — the assumption is that medication alone will do most of the heavy lifting. This appeals to individuals seeking convenience, especially if they’ve struggled to get prescriptions through traditional routes.

Meto is built on a different philosophy: that medication is a tool, not a cure. Rather than centering the patient journey around semaglutide, Meto uses it as part of a medical care plan rooted in metabolic, hormonal, and behavioral science. The platform addresses the “why” behind weight issues — from insulin resistance to adrenal dysfunction — and matches patients with a licensed provider who stays with them throughout the journey. Meto integrates lab testing, coaching, nutrition guidance, and deprescription planning to help patients not just lose weight, but restore long-term health.

Henry Meds provides minimal clinical interaction. After completing a brief form, users speak to a provider (virtually) to determine eligibility for GLP-1 medications. Once approved, they receive monthly shipments of compounded semaglutide or tirzepatide. While the service meets basic clinical standards, there’s no ongoing provider-patient relationship. Follow-ups are generally limited to dosage adjustments and prescription renewals, with little or no monitoring of long-term progress, side effects, or health metrics outside of weight.

Meto delivers care through a coordinated, expert-led team that includes board-certified physicians, dietitians, and health coaches. From day one, patients undergo clinical onboarding that includes lab work, symptom analysis, and biomarker tracking. Providers work closely with patients to develop a long-term care strategy that may include GLP-1s — but also evaluates when they’re necessary, how to taper, and how to complement them with sustainable lifestyle changes. Ongoing supervision, regular check-ins, and real-time insights via wearable and lab data make Meto feel more like a virtual clinic than a quick prescription service.

Henry Meds uses a templated approach to prescribing GLP-1s. Most users follow a standard protocol: start on a low dose, titrate monthly, and continue until results plateau. The service doesn’t include biomarker testing, symptom tracking, or hormonal assessments — so personalization is limited to dosage and drug choice (semaglutide or tirzepatide). There’s no mechanism for tailoring care based on things like thyroid health, insulin resistance, or menstrual cycles.

Meto, by contrast, delivers full-spectrum personalization from the start. Users complete a comprehensive intake that informs customized treatment plans — including lab results, metabolic profiles, health history, and lifestyle data. A care team works with patients to adjust their program continuously based on changing biomarkers, symptoms, goals, and feedback. Whether a patient is experiencing perimenopausal weight gain or GLP-1-related side effects, the plan evolves with their needs, backed by clinical oversight.

GLP-1s are the heart of Henry Meds’ offering. Every subscriber receives either semaglutide or tirzepatide (compounded), depending on provider approval. The medications are shipped monthly, and customer service supports questions about delays or side effects. But there’s no broader clinical plan — and little guidance on how to integrate GLP-1s into your lifestyle or eventually taper off. It’s access, not long-term care.

Meto takes a clinical approach to GLP-1 use. Prescriptions are only written after a thorough medical evaluation, and only when clinically appropriate. Once prescribed, Meto supports patients through titration, symptom monitoring, lab analysis, and behavior coaching. The platform emphasizes deprescription — with a goal of helping patients eventually come off medication while maintaining their results. GLP-1s are seen not as the solution, but one piece of a bigger picture that includes whole-body health.

Henry Meds may be a good fit for those who want fast, direct access to GLP-1 medications without involving insurance or traditional doctor visits. It’s ideal for people who already know they want semaglutide or tirzepatide and don’t feel they need coaching, lab work, or long-term clinical care. However, this approach may fall short for those with complex medical histories or those looking to address the root causes of their weight struggles.

Meto is designed for people who want more than just a prescription. If you’re dealing with metabolic issues like PCOS, thyroid disorders, menopause symptoms, or insulin resistance — or you’ve tried weight loss medications before without success — Meto offers a more complete solution. It’s also ideal for those who value clinical support, care continuity, and personalized guidance throughout their weight care journey. If your goal is long-term health, not just short-term weight loss, Meto is built for you.